This inventor holds 1 USPTO granted patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Apollon Papdimitriou: Innovator in Cancer Treatment
Introduction
Apollon Papdimitriou is a notable inventor based in Bichl, Germany. He has made significant contributions to the field of cancer treatment through his innovative research and development.
Latest Patents
Papdimitriou holds a patent for "PEG conjugates of NK4." This invention provides a conjugate consisting essentially of an NK4 molecule and a polyethylene glycol group with a molecular weight ranging from about 20 to about 40 kDa. The patent also details a composition where the monoPEGylated conjugates comprise at least 90% of the total pegylated NK4 molecules and unpegylated NK4 molecules. Furthermore, it describes a method for treating cancer by administering 1 to 30 mg of monoPEGylated NK4 per kg per day.
Career Highlights
Apollon Papdimitriou is associated with Hoffmann-La Roche Inc., where he continues to advance his research in the pharmaceutical industry. His work focuses on developing innovative solutions for cancer treatment, showcasing his commitment to improving patient outcomes.
Collaborations
Papdimitriou collaborates with various professionals in his field, including his coworker Michael Brandt. Their combined expertise contributes to the ongoing development of effective cancer therapies.
Conclusion
Apollon Papdimitriou is a dedicated inventor whose work in PEG conjugates of NK4 represents a significant advancement in cancer treatment. His contributions to the field highlight the importance of innovation in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile